GLP1R and metabolic dysfunction-associated steatotic liver disease: To date, various co-agonists have been engineered that could simultaneously target critical receptors involved in the NAFLD, such as GLP-1R, glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR), glucagon receptor (GCGR) [87], PPARα, PPARβ/δ, and PPARγ [88,89].